The AAAAI seeks to clarify and ensure reimbursement for telehealth and other vital health care services during this pandemic to ensure practicing allergist/immunologists can continue to provide optimal patient care during these unprecedented times.
Continually updated links from AAAAI’s professional advocacy team, Hart Health Strategies
The AAAAI partners with Hart Health Strategies to provide ongoing advocacy with Congress, federal regulatory agencies, and other important strategic outreach. We are pleased to provide links to documents the Hart Health team is keeping up to date to provide you with the latest important information on critical issues related to COVID-19. Check these links often for the latest information.
• Small Business Resources
• Health Care Workers on the Front Lines
• Personal Protective Equipment
• Disaster Primer
• State Resources
• COVID-19 Testing
• Federal Relief Overview
• Telehealth Overview
• Hospice and Palliative Care
• Physician Provisions
• Tax Provisions
• Small Business - Paycheck Protection Program
• Nursing Resources
• Small Business – PPP FAQ
AAAAI COVID-19 Advocacy Activity
August 19, 2020
The AAAAI has signed on to a letter to the leadership of the US House of Representatives in support of providing additional funding for AHRQ for study of critical issues in healthcare systems in the US, particularly those impacting veterans, low income communities, and the elderly, with particular attention to studying healthcare disparities and inequities demonstrated and exacerbated by the pandemic.
July 30, 2020
Support for in-home IVIG infusion services
The AAAAI sent a letter to Representatives Brady and Matsui to express enthusiastic support for H.R. 7839, the Continuing Access to In-Home IVIG Act, legislation they have sponsored to ensure Medicare beneficiaries with PI diseases have access to the Medicare Part B home infusion benefit. The AAAAI is pleased to continue to support efforts on this important issue.
July 16, 2020
The AAAAI has sent a letter to Secretary Alex Azar asking that HHS allow providers who missed the June 3 deadline to apply for additional CARES Act Provider Relief Fund disbursements. This letter is in response to AAAAI members who reached out to firstname.lastname@example.org after receiving a minimal relief payment based on a very small Medicare patient population in their practice, not knowing that the Medicare relief would make them ineligible under subsequent Medicaid relief, which represents a much greater portion of their practice; and thus missed the June 3 deadline.
June 25, 2020
The AAAAI has urged payers nationwide to extend the deadline for all expanded telehealth services for at least 90 days beyond the expiration of the nationwide Public Health Emergency, if not permanently. Read the letter sent to: Aetna, Amerigroup, Amerihealth, Anthem, Blue Cross Blue Shield Association, Blue Cross Blue Shield of Illinois, Blue Cross Blue Shield of Montana, Blue Cross Blue Shield of New Mexico, Blue Cross Blue Shield of Oklahoma, Blue Cross Blue Shield of Texas, CareFirst Blue Cross, Centene, Humana, Molina Health Care, UnitedHealth Care and Wellmark.
June 17, 2020
The AAAAI has urged the U.S. Senate Committee on Health, Education Labor & Pensions and Congress to make permanent the new telehealth flexibilities provided by the Centers for Medicare and Medicaid Services (CMS) in response to the COVID-19 pandemic. Read the letter here.
June 3, 2020
AAAAI Virtual Advocacy Day
The AAAAI hosted a Virtual Advocacy Day focused on three issues: increasing federal funding for food allergy research; the School-Based Allergies and Asthma Management Program Act (H.R. 2468); and extending telemedicine policies to protect provider and patient safety, and patient access to specialty care.
May 7, 2020
The AAAAI has sent a letter to Secretary Azar asking that changes to virtual care and telemedicine policies made for the COVID19 pandemic be extended beyond the announced dates, and that authority be sought through Congressional action to influence private payer coverage at parity with in person services for some office visits.
April 24, 2020
AAAAI has asked CMS to implement many of the temporary telehealth services policies on a permanent basis, waive the “video” requirement for furnishing office/outpatient E/M services, and expressed caution regarding efforts to facilitate at-home administration of infused or injected medications. View the letter here.
April 15, 2020
The AAAAI continues to actively promote the interests of Allergist/Immunologists on the issues impacting the entire healthcare industry during the COVID-19 crisis, both independently and through important coalitions and consortia. Looking forward, the AMA has coordinated a letter to Congressional leadership specifically addressing needs in a “phase 4” package.
March 25, 2020
AAAAI joined the AMA and others in Congressional advocacy on the economic stimulus package
The AAAAI joined a broad group of organizations advocating for physicians to be included in financial assistance in a Congressional relief package intended to mitigate economic impacts of COVID-19. View the letter here.
March 18, 2020
AAAAI letter to CMS advocating for private payer coverage for COVID-19 telemedicine visits
The AAAAI has sent a letter to CMS Administrator Seema Verma supporting recent comments regarding working with private payers to cover telemedicine visits for patients.
March 17, 2020
AAAAI advocates for home infusion coverage amid COVID-19 concerns
The AAAAI consistently advocates for concerns for immune-deficient patients. We have signed on in support of a coalition effort prioritizing protecting in-home infusion in light of the COVID-19 crisis in the House and Senate.
March 16, 2020
AAAAI letter to Sen. Romney regarding telemedicine services
The AAAAI supports Senator Romney’s efforts to increase access to telemedicine service to patients with private insurance, as well as Medicare and Medicaid patients.